Fagron

FAGR.BRPre-clinical

Antwerp, BelgiumFounded 1990fagron.com

Fagron is a leading global player in pharmaceutical compounding, dedicated to widening the therapeutic scope of prescribers through innovation in personalized medicine. The company leverages its proprietary platforms like Lollibase® and Pentravan®, along with its extensive Fagron Formulary and Fagron Academy, to support the creation of patient-specific medications. With a strategic focus on compounding science, a global commercial footprint, and a commitment to ESG principles, Fagron aims to be the central hub for compounding knowledge and solutions worldwide.

Market Cap

$1.8B

Founded

1990

Employees

4,000+

Focus

Drug Delivery

FAGR.BR · Stock Price

USD 21.65+4.08 (+23.22%)

Historical price data

AI Company Overview

Technology Platform

Integrated ecosystem for pharmaceutical compounding, including proprietary excipient bases (Lollibase®, Pentravan®), a global formulation database (Fagron Formulary), a digital training academy, and compounding equipment (FagronLab™).

Funding History

IPOUndisclosedUndisclosedJun 15, 1997

Opportunities

Growth is driven by the global trend towards personalized medicine, aging populations, and niche therapeutic needs.

Opportunities exist in expanding the proprietary product portfolio, deepening penetration in key markets like North America, leveraging the Fagron Academy for customer loyalty, and integrating genomic data into compounding practices.

Risk Factors

Key risks include stringent and evolving global regulations on compounding, vulnerabilities in the international API supply chain, potential reputational damage from industry safety issues, and competitive pressure from large pharmaceutical distributors.

Competitive Landscape

Fagron competes with large chemical distributors (e.g., Merck, Thermo Fisher) and regional compounding suppliers. Its differentiation lies in its global integrated ecosystem of proprietary bases, scientific formulations, training, and equipment tailored specifically for the compounding pharmacy market.

Publications

Patents